Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
23andMe, a company known for DNA testing, is facing challenges as mass-market genetic testing is found to have limited benefits for most people. The company's focus on genetic differences is questioned, with critics highlighting the lack of significant impact. Despite having data from 15 million users, 23andMe is struggling and risks being delisted from Nasdaq.
Shares of this gene editing company are due to surge more than 45%, Citi says https://t.co/jPOuPGod61
In #SyntheticBiology news, BTIG on Wednesday downgraded shares of Ginkgo Bioworks to a Sell rating with a price target of $0.50. Ginkgo $DNA shares were at $14 during the 2021 #biotech boom, but they've been trading as a penny stock for a while now. https://t.co/6uylPsznsH https://t.co/AE7XwIVyiB
23andMe, on verge of being delisted from Nasdaq, is still waiting for a revolution in debugging our DNA. Its greatest asset is data from 15 million users it mines for potential drugs. (Though they haven't told me why I have clumpy platelets) https://t.co/cY8gGnze0z @BW
